TP53 and acute myeloid leukemia: Another class of targets are MDM2 (murine double minute 2 or human homolog HDM2) inhibitors that act as a physiologic antagonist of p53, which activates p53 and induces apoptosis or cell cycle arrest in wild-type p53-expressing AML.